Accuray (ARAY) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Announced a major organizational, strategic, and operational transformation to drive performance and growth, with most initiatives to be implemented during the current fiscal year.
Appointed Steve La Neve as CEO, succeeding Suzanne Winter, who will remain as an advisor through November 2025.
Steven F. Mayer named Transformation Board Sponsor to lead planning and execution of transformation initiatives.
Transformation plan aims to increase operating margins, enhance agility, and position for sustainable, profitable growth.
Preliminary Q1 FY2026 results show service revenues ahead of plan, but product revenues below expectations in EIMEA and China; total revenues estimated at $92.5–$94 million, with adjusted EBITDA at approximately ($4) million.
Voting matters and shareholder proposals
Shareholders will be asked to approve the 2026 Equity Incentive Plan at the 2025 Annual Meeting, enabling new equity awards for executives and consultants.
Chan W. Galbato nominated to the Board of Directors, bringing extensive operational and board experience.
Board of directors and corporate governance
Board appointed Steve La Neve as CEO and Steven F. Mayer as Transformation Board Sponsor.
Board to adopt resolutions conferring authority to the Transformation Board Sponsor for leading transformation initiatives.
Board nominated Chan W. Galbato, a seasoned executive and board member, to join the Board.
Latest events from Accuray
- Shelf registration covers resale of 7M shares from warrants tied to recent financing.ARAY
Registration Filing17 Feb 2026 - Revenue and margin guidance cut as China headwinds, tariffs, and financing changes weigh.ARAY
Q2 202617 Feb 2026 - Record Q4 revenue and robust FY25 outlook highlight strong growth and global expansion.ARAY
Q4 20241 Feb 2026 - Growth driven by innovation, emerging markets, and margin expansion, with U.S. recovery expected.ARAY
Jefferies Global Healthcare Conference31 Jan 2026 - FY2025 guidance raised as China growth and service gains offset margin and revenue declines.ARAY
Q1 202516 Jan 2026 - Q3 FY25 revenue up 12%, net loss narrowed, but guidance cut on tariffs; EBITDA improved.ARAY
Q3 202527 Dec 2025 - Q2 revenue up 8% to $116.2M, net income $2.5M, margin 36.1%, guidance raised.ARAY
Q2 202524 Dec 2025 - Resale registration covers 23.4M shares from warrant exercises tied to recent financing.ARAY
Registration Filing16 Dec 2025 - Shareholders will vote on director elections, equity plan increases, pay, and auditor ratification.ARAY
Proxy Filing1 Dec 2025